Subscribe
celgene-logo
Photo: Courtesy of Celgene ( Celgene Logo, https://www.celgene.com/media-library/celgene-logo/)
29 September 2015Americas

Celgene reiterates stance on Kyle Bass IPRs

Biopharmaceutical company Celgene has reiterated its stance on the inter partes review (IPR) petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB grants IPR of Celgene patents after Kyle Bass challenge
28 October 2015   The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
PTAB grants IPR of Celgene patents after Kyle Bass challenge
28 October 2015   The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.

More on this story

Americas
PTAB grants IPR of Celgene patents after Kyle Bass challenge
28 October 2015   The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits